Finfeed is following on from one of Australia’s most successful biotech and life sciences fund managers to select and invest in early to mid-stage ASX listed biotechs.
| Stocks |
Date of Initial Coverage
|
Initial Entry Price
|
Last Price
|
Portfolio Weighting | Shares Held | Macro Theme | Actively Sharing | Highest Point |
Performance from Initial Entry
|
|---|---|---|---|---|---|---|---|---|---|
| EMD | 04-Sep-2023 | $0.075 | $0.059 | Biotech | 65% | -21% | |||
| ALA | 18-Feb-2022 | $0.038 | $0.105 | Biotech | 387% | 176% | |||
| DXB | 16-Aug-2021 | $0.200 | $0.300 | Biotech | 85% | 50% | |||
| NTI | 18-Sep-2023 | $0.045 | $0.105 | None | 191% | 135% |
| Stocks |
Date of Initial Coverage
|
Initial Entry Price
|
Last Price
|
Portfolio Weighting | Shares Held | Macro Theme | Actively Sharing | Highest Point |
Performance from Initial Entry
|
|---|---|---|---|---|---|---|---|---|---|
| EMD | 04-Sep-2023 | $0.075 | $0.059 | Biotech | 65% | -21% | |||
| ALA | 18-Feb-2022 | $0.038 | $0.105 | Biotech | 387% | 176% | |||
| DXB | 16-Aug-2021 | $0.200 | $0.300 | Biotech | 85% | 50% | |||
| NTI | 18-Sep-2023 | $0.045 | $0.105 | None | 191% | 135% |